Long-Term Management with Adipose Tissue-Derived Mesenchymal Stem Cells and Conventional Treatment in a Dog with Hepatocutaneous Syndrome

The document described the long-term management of a 10-year-old Maltese dog with hepatocutaneous syndrome (HS) using adipose tissue-derived mesenchymal stem cells (AD-MSCs) alongside conventional treatments. Over 30 months, the dog received 46 infusions of AD-MSCs, resulting in significant improvements in skin lesions and overall health, including hair regrowth. Despite these benefits, the dog eventually developed severe azotemia and died 32 months after diagnosis. Postmortem examination revealed severe liver fibrosis and necrolytic dermatitis. The study suggested that combining amino acid and stem cell therapy could extend survival beyond the typical 6 months for HS patients, though further research was needed to isolate the effects of MSCs.